Salmonella enterica serovar Typhi live vector vaccines finally come of age

Immunology and Cell Biology

Volumn 87, Issue 5, 2009, Pages 400-412

  Galen, James E ^a   Pasetti, Marcela F ^a   Tennant, Sharon ^a   Ruiz Olvera, Patricia ^a   Sztein, Marcelo B ^a   Levine, Myron M ^a  

^a University of Maryland School of Medicine Center for Vaccine Development   (United States)

Author keywords

Clinical; Fitness; Immunogenicity; Live vector; Overattenuated; Typhi

Indexed keywords

ANTIBODY; BACTERIAL ANTIGEN; BACTERIUM VECTOR; ESCHERICHIA COLI VACCINE; GENE THERAPY AGENT; HELICOBACTER PYLORI VACCINE; HEPATITIS B VACCINE; IMMUNOGLOBULIN G; MALARIA VACCINE; PA83 ANTIBODY; T LYMPHOCYTE ANTIGEN; TETANUS TOXOID; UNCLASSIFIED DRUG;

BACTERIAL STRAIN; CHROMOSOME INSERTION; ESCHERICHIA COLI INFECTION; HELICOBACTER INFECTION; HEPATITIS B; HUMAN; IMMUNITY; MALARIA; NONHUMAN; PLASMID; PROTEIN EXPRESSION; REVIEW; SALMONELLA ENTERICA; TETANUS; VACCINATION;

ANIMALS; ANTIGENS; CLINICAL TRIALS AS TOPIC; DNA, RECOMBINANT; GENETIC VECTORS; HUMANS; IMMUNIZATION; SALMONELLA TYPHI; VACCINES, ATTENUATED;

ANIMALIA; BACTERIA (MICROORGANISMS); SALMONELLA ENTERICA SUBSP. ENTERICA SEROVAR TYPHI; SALMONELLA TYPHI;

EID: 68149145653     PISSN: 08189641     EISSN: 14401711     Source Type: Journal    
DOI: 10.1038/icb.2009.31     Document Type: Review

References (122)

1. Dougan G, Hormaeche CE, Maskell DJ. Live oral Salmonella vaccines: potential use of attenuated strains as carriers of heterologous antigens to the immune system. Parasite Immunol 1987; 9: 151-160.
2. Levine MM, Hone DM, Noriega F, Sriwathana B. Attenuated Salmonella as carriers for the expression of foreign antigens. Microecol Therapy 1990; 19:23-32.
3. Levine MM, Tacket CO, Sztein MB. Host-Salmonella interaction: human trials. Microbes Infect 2001; 3: 1271-1279.
4. Sztein MB, Tanner MK, Polotsky Y, Orenstein JM, Levine MM. Cytotoxic T lymphocytes after oral immunization with attenuated vaccine strains of Salmonella typhi in humans. JImmunol 1995; 155: 3987-3993.
5. Sztein MB. Cell-mediated immunity and antibody responses elicited by attenuated Salmonella enterica serovar Typhi strains used as live oral vaccines in humans. Clin Infect Dis 2007; 45 (Suppl 1): S15-S19.
6. Salerno-Goncalves R, Fernandez-Vina M, Lewinsohn DM, Sztein MB. Identification of a human HLA-E-restricted CD8+ Tcell subset in volunteers immunized with Salmonella enterica serovar Typhi strain Ty21a typhoid vaccine. J Immunol 2004; 173: 5852-5862.
7. Sztein MB, Wasserman SS, Tacket CO, Edelman R, Hone D, Lindberg AA et al. Cytokine production patterns and lymphoproliferative responses in volunteers orally immunized with attenuated vaccine strains of Salmonella typhi. JInfectDis1994; 170: 1508-1517.
8. Chatfield SN, Charles IG, Makoff AJ, Oxer MD, Dougan G, Pickard D et al. Use of the nirB promoter to direct the stable expression of heterologous antigens in Salmonella oral vaccinestrains: developmentofa single-doseoral tetanusvaccine. Biotechnology (NY)1992; 10: 888-892.
9. Li Y, Wang S, Xin W, Scarpellini G, Shi Z, Gunn B et al. A sopB deletion mutation enhances the immunogenicity and protective efficacy of a heterologous antigen delivered by live attenuated Salmonella enterica vaccines. Infect Immun 2008; 76: 5238-5246.
10. LevineMM, Taylor DN, Ferreccio C. Typhoid vaccines comeof age. PediatrInfectDis J 1989; 8: 374-381.
11. Levine MM, Ferreccio C, Black RE, Germanier R. Large-scale field trial of Ty21a live oral typhoid vaccine in enteric-coated capsule formulation. Lancet 1987; 1: 1049-1052.
12. Hohmann EL, Oletta CA, Killeen KP, Miller SI. phoP/phoQ-Deleted Salmonella typhi (Ty800) is a safe and immunogenic single-dose typhoid fever vaccine in volunteers. JInfect Dis 1996; 173: 1408-1414.
13. Tacket CO, Hone DM, Losonsky GA, Guers L, Edelman R, Levine MM. Clinical acceptability and immunogenicity of CVD 908 Salmonella typhi vaccine strain. Vaccine 1992; 10: 443-446.
14. Hone DM, Harris AM, Chatfield S, Dougan G, Levine MM. Construction of genetically defined double aro mutants of Salmonella typhi. Vaccine 1991; 9: 810-816.
15. TacketCO, Hone DM, Curtiss III R, Kelly SM, Losonsky G, Guers L et al. Comparison of the safety and immunogenicity of DaroCDaroD and DcyaDcrp Salmonella typhi strains in adult volunteers. Infect Immun 1992; 60: 536-541.
16. Tacket CO, Sztein M, Losonsky G, Wasserman SS, Nataro JP, Edelman R et al. Safety of live oral Salmonella typhi vaccine strains with deletions in htrA and aroC aroD and immune responses in humans. Infect Immun 1997; 65:452-456.
17. Tacket CO, Sztein M, Wasserman SS, Losonsky G, Kotloff K, Wyant TL et al. Phase 2 clinical trial of attenuated Salmonella enterica serovar Typhi oral live vector vaccine CVD 908-htrA in U.S. volunteers. Infect Immun 2000; 68: 1196-1201.
18. Wang JY, Noriega F, Galen JE, Barry EM, Levine MM. Constititive expression of the Vi polysaccharide capsular antigen in attenuated Salmonella enterica serovar Typhi oral vaccine strain CVD 909. Infect Immun 2000; 68: 4647-4652.
19. Tacket CO, Pasetti MF, Sztein MB, Livio S, Levine MM. Immune responses to an oral typhoid vaccine strain that is modified to constitutively express Vi capsular polysaccharide. JInfect Dis 2004; 190:565-570.
20. Hindle Z, Chatfield SN, Phillimore J, Bentley M, Johnson J, Cosgrove CA et al. Characterization of Salmonella enterica derivatives harboring defined aroC and Salmonella pathogenicity island 2 type III secretion system (ssaV) mutations by immunization of healthy volunteers. Infect Immun 2002; 70: 3457-3467.
21. Kirkpatrick BD, Tenney KM, Larsson CJ, O'Neill JP, Ventrone C, Bentley M et al. The novel oral typhoid vaccine M01ZH09 is well tolerated and highlyimmunogenic in 2 vaccine presentations. JInfect Dis 2005; 192: 360-366.
22. Kirkpatrick BD, McKenzie R, O'Neill JP, Larsson CJ, Bourgeois AL, Shimko J et al. Evaluation of Salmonella enterica serovar Typhi (Ty2 aroC-ssaV-) M01ZH09, with a defined mutation in the Salmonella pathogenicity island 2, as a live, oral typhoid vaccine in human volunteers. Vaccine 2006; 24: 116-123.
23. Li Y, Wang S, Scarpellini G, Gunn B, Xin W, Wanda SY et al. Evaluation of new generation Salmonella enterica serovar Typhimurium vaccines with regulated delayed attenuation to induce immune responses against PspA. Proc Natl Acad Sci USA 2009; 106: 593-598.
24. Curtiss III R, Wanda SY, Gunn BM, Zhang X, Tinge SA, Ananthnarayan V et al. Salmonella strains with regulated delayed attenuation in vivo. Infect Immun 2009; 3: 1071-1082.
25. HusseinyMI, Hensel M. Construction ofhighlyattenuatedSalmonellaentericaserovar Typhimurium live vectors for delivering heterologous antigens by chromosomal integration. Microbiol Res2008; 163:605-615.
26. Cardenas L, Clements JD. Stability, immunogenicity and expression of foreign antigens in bacterial vaccine vectors. Vaccine 1993; 11:126-135.
27. Garmory HS, Titball RW, Griffin KF, Hahn U, Bohm R, Beyer W. Salmonella enterica serovar typhimurium expressing a chromosomally integrated copy of the Bacillus anthracis protective antigen gene protects mice against an anthrax spore challenge. Infect Immun 2003; 71: 3831-3836.
28. Hohmann EL, OlettaCA, LoomisWP, Miller SI. Macrophage-inducibleexpression ofa model antigen in Salmonellatyphimuriumenhancesimmunogenicity. ProcNatlAcad Sci USA 1995; 92: 2904-2908.
29. Stratford R, McKelvie ND, Hughes NJ, Aldred E, Wiseman C, Curtis J et al. Optimization of Salmonella enterica serovar typhi DeltaaroC DeltassaVderivatives as vehicles for delivering heterologous antigens by chromosomal integration and in vivo inducible promoters. Infect Immun 2005; 73: 362-368.
30. Valdivia RH, Falkow S. Fluorescence-based isolation of bacterial genes expressed within host cells. Science 1997; 277: 2007-2011.
31. Khan SA, Stratford R, Wu T, Mckelvie N, BellabyT, Hindle Z et al. Salmonella typhi and S typhimurium derivatives harbouring deletions in aromatic biosynthesis and Salmonella pathogenicity island-2 (SPI-2) genes as vaccines and vectors. Vaccine 2003; 21: 538-548.
32. Thomas CM. Paradigmsofplasmid organization. MolMicrobiol2000; 37: 485-491.
33. Thomas CM. Evolution and population genetics of bacterial plasmids. In: Funnell BE, Phillips GJ (eds). Plasmid Biology, 1st edn. ASM Press: Washington, DC, 2004, pp 509-528.
34. Galen JE, Nair J, WangJY, Wasserman SS, TannerMK, Sztein M et al. Optimization of plasmid maintenance in the attenuated live vector vaccine strain Salmonella typhi CVD 908-htrA. Infect Immun 1999; 67: 6424-6433.
35. Galen JE, Chinchilla M, Pasetti MF, Wang JY, Zhao L, Arciniega-Martinez I et al. Mucosal immunization with attenuated Salmonella enterica serovar Typhi expressing protective antigen from anthrax toxin (PA83) primes monkeys for accelerated serum antibodyresponses to parenteral PA83 vaccine. JInfectDis2009; 199: 326-335.
36. Summers DK, Sherratt DJ. Multimerization of high copy number plasmids causes instability: ColE1 encodes a determinant essential for plasmid monomerization and stability. Cell 1984; 36: 1097-1103.
37. Summers DK, Beton CW, Withers HL. Multicopy plasmid instability: the dimer catastrophe hypothesis. Mol Microbiol 1993; 8: 1031-1038.
38. Hodgman TC, Griffiths H, Summers DK. Nucleoprotein architecture and ColE1 dimer resolution: a hypothesis. Mol Microbiol 1998; 29: 545-558.
39. Krause M, Guiney DG. Identification of a multimer resolution system involved in stabilization of the Salmonella dublin virulence plasmid pSDL2. JBacteriol1991; 173: 5754-5762.
40. Szczepanowski R, Braun S, Riedel V, Schneiker S, Krahn I, Puhler A et al. The 120 592 bpIncF plasmid pRSB107 isolated from asewage- treatmentplantencodesnine different antibiotic-resistance determinants, two iron-acquisition systems and other putative virulence-associated functions. Microbiology2005; 151: 1095-1111.
41. Stephens JC, Darsley MJ, Turner AK. Stabilization of a plasmid coding for a heterologous antigen in Salmonella enterica serotype typhi vaccine strain CVD908- htrA by using site-specific recombination. Infect Immun 2006; 74: 4383-4386.
42. Pittard AJ. Biosynthesis of the aromatic amino acids. In: Neidhardt FC, Curtiss III R, Ingraham JL, Lin ECC, Low KB, Magasanik B, et al.(eds).Escherichia Coli and Salmonella: Cellular and Molecular Biology, 2nd edn. ASM Press: Washington, DC, 1996, pp 458-484.
43. Galan JE, Nakayama K, Curtiss III R. Cloning and characterization of theasdgeneof Salmonella typhimurium: use in stable maintenance of recombinant plasmids in Salmonella vaccine strains. Gene 1990; 94:29-35.
44. Karem KL, Chatfield S, Kuklin N, Rouse BT. Differential induction of carrier antigen- specific immunity by Salmonella typhimurium live-vaccine strains after single mucosal or intravenous immunization of BALB/c mice. Infect Immun 1995; 63: 4557-4563.
45. Covone MG, Brocchi M, Palla E, da Silveira WD, Rappuoli R, Galeotti CL. Levels of expression and immunogenicity of attenuated Salmonella enterica serovar typhimur- ium strains expressing Escherichia coli mutant heat-labile enterotoxin. Infect Immun 1998; 66: 224-231.
46. Schodel F, Kelly SM, Peterson DL, Milich DR, Curtiss III R. Hybrid hepatitis B virus core-pre-S proteins synthesized in avirulent Salmonella typhimurium and Salmonella typhi for oral vaccination. Infect Immun 1994; 62: 1669-1676.
47. Yang X, Hinnebusch BJ, Trunkle T, Bosio CM, Suo Z, Tighe M et al. Oral vaccination with SalmonellasimultaneouslyexpressingYersiniapestisF1 and Vantigensprotects againstbubonic and pneumonic plague. JImmunol2007; 178: 1059-1067.
48. Cranenburgh RM, Lewis KS, Hanak JA. Effect of plasmid copy number and lac operator sequenceon antibiotic-free plasmid selection byoperator-repressor titration in Escherichia coli. JMol Microbiol Biotechnol 2004; 7: 197-203.
49. Garmory HS, Leckenby MW, Griffin KF, Elvin SJ, Taylor RR, Hartley MG et al. Antibiotic-freeplasmid stabilization byoperator-repressor titration forvaccinedelivery by using live Salmonella enterica serovar typhimurium. Infect Immun 2005; 73: 2005-2011.
50. Chase JW, Williams KR. Single-stranded DNA binding proteins required for DNA replication. Annu Rev Biochem 1986; 55: 103-136.
51. Lohman TM, Ferrari ME. Escherichia coli single-stranded DNA-binding protein: multiple DNA-binding modes and cooperativities. Annu Rev Biochem 1994; 63: 527-570.
52. Khan CM, Villarreal-Ramos B, Pierce RJ, Demarco DH, McNeill H, Ali T et al. Construction, expression, and immunogenicity of multiple tandem copies of the Schistosoma mansoni peptide 115-131 of the P28 glutathione S-transferase expressed as C-terminal fusions to tetanus toxin fragment C in a live aro-attenuated vaccine strain of Salmonella. JImmunol1994; 153: 5634-5642.
53. McSorley SJ, Xu D, Liew FY. Vaccine efficacy of Salmonella strains expressing glycoprotein 63 with different promoters. InfectImmun 1997; 65: 171-178.
54. Bumann D. Regulated antigen expression in live recombinant Salmonella enterica serovar Typhimurium strongly affects colonization capabilities and specific CD4+-T- cell responses. Infect Immun 2001; 69: 7493-7500.
55. GalenJE, Levine MM. Can a'flawless' live vector vaccine strain be engineered? Trends Microbiol 2001; 9:372-376.
56. Kang HY, Curtiss III R. Immune responses dependent on antigen location in recombinant attenuated Salmonella typhimurium vaccines following oral immunization. FEMS Immunol MedMicrobiol 2003; 37: 99-104.
57. KangHY, SrinivasanJ, CurtissIII R. Immuneresponsestorecombinantpneumococcal PspA antigen delivered by live attenuated Salmonella enterica serovar typhimurium vaccine. Infect Immun 2002; 70: 1739-1749.
58. Xin W, Wanda SY, Li Y, Wang S, Mo H, Curtiss III R. Analysis of type II secretion of recombinant pneumococcal PspA and PspC in a Salmonella enterica serovar Typhi- murium vaccine with regulated delayed antigen synthesis. Infect Immun 2008; 76: 3241-3254.
59. Hess J, Gentschev I, Miko D, Welzel M, Ladel C, Goebel W et al. Superior efficacy of secreted over somatic antigen display in recombinant Salmonella vaccine induced protection againstlisteriosis. Proc Natl AcadSci USA 1996; 93: 1458-1463.
60. Russmann H, Igwe EI, Sauer J, Hardt WD, Bubert A, Geginat G. Protection against murine listeriosis byoral vaccination with recombinant Salmonella expressing hybrid Yersinia type III proteins. JImmunol2001; 167: 357-365.
61. Chen LM, BrionesG, DonisRO, Galan JE. Optimization ofthedeliveryofheterologous proteins by the Salmonella enterica serovar Typhimurium type III secretion system for vaccine development. Infect Immun 2006; 74: 5826-5833.
62. Husseiny MI, Wartha F, Hensel M. Recombinant vaccines based on translocated effector proteinsofSalmonellaPathogenicityIsland 2. Vaccine2007; 25:185-193.
63. Galen JE, Zhao L, ChinchillaM, WangJY, Pasetti MF, Green J et al. Adaptation of the endogenous Salmonella enterica serovar Typhi clyA-encoded hemolysin for antigen export enhances the immunogenicity of anthrax protective antigen domain 4 expressed by the attenuated live-vector vaccine strain CVD 908-htrA. Infect Immun 2004; 72: 7096-7106.
64. Oscarsson J, Westermark M, Lofdahl S, Olsen B, Palmgren H, Mizunoe Y et al. Characterization of a pore-forming cytotoxin expressed by Salmonella enterica ser- ovars typhi and paratyphi A. Infect Immun 2002; 70: 5759-5769.
65. Wallace AJ, Stillman TJ, Atkins A, Jamieson SJ, Bullough PA, Green J et al. E. coli hemolysin E (HlyE, ClyA, SheA): X-raycrystal structureof thetoxin and observation of membrane pores by electron microscopy. Cell 2000; 100: 265-276.
66. Eifler N, Vetsch M, Gregorini M, Ringler P, Chami M, Philippsen A et al. Cytotoxin ClyA from Escherichia coli assembles to a 13-meric pore independent of its redox-state. EMBO J2006; 25: 2652-2661.
67. del Castillo FJ, Moreno F, del Castillo I. Secretion of theEscherichiacoli K-12 SheA hemolysin is independent of its cytolytic activity. FEMS Microbiol Lett 2001; 204: 281-285.
68. Wai SN, Lindmark B, Soderblom T, Takade A, Westermark M, Oscarsson J et al. Vesicle-mediated exportand assemblyof pore-formingoligomers of the enterobacter- ial ClyA cytotoxin. Cell 2003; 115:25-35.
69. Chinchilla M, Pasetti MF, Medina-Moreno S, Wang JY, Gomez-Duarte OG, Stout R et al. Enhanced immunity to Plasmodium falciparum circumsporozoite protein (PfCSP) by using Salmonella enterica serovar Typhi expressing PfCSP and a PfCSP- encoding DNA vaccine in a heterologous prime-boost strategy. Infect Immun 2007; 75: 3769-3779.
70. Baillie LW, Rodriguez AL, Moore S, Atkins HS, Feng C, Nataro JP et al. Towards a human oral vaccinefor anthrax: theutilityof a SalmonellaTyphi Ty21a-based prime- boost immunization strategy. Vaccine2008; 26: 6083-6091.
71. Stokes MG, Titball RW, Neeson BN, Galen JE, Walker NJ, Stagg AJ et al. Oral administration of a Salmonella enterica-based vaccine expressing Bacillus anthracis protective antigen confers protection against aerosolized Banthracis. Infect Immun 2007; 75: 1827-1834.
72. Bauer H, Darji A, Chakraborty T, Weiss S. Salmonella-mediated oral DNA vaccination using stabilized eukaryotic expression plasmids. Gene Ther2005; 12:364-372.
73. Pasetti MF, Anderson RJ, NoriegaFR, LevineMM, Sztein MB. Attenuated deltaguaBA Salmonella typhi vaccine strain CVD 915 as a live vector utilizing prokaryotic or eukaryotic expression systems to deliver foreign antigens and elicit immune responses. Clin Immunol 1999; 92:76-89.
74. Flo J, Tisminetzky S, Baralle F. Oral transgene vaccination mediated by attenuated Salmonellaeisan effectivemethodto preventherpessimplexvirus-2 induceddisease in mice. Vaccine2001; 19: 1772-1782.
75. ShataMT, Reitz Jr MS, DevicoAL, LewisGK, HoneDM. Mucosal and systemic HIV-1 Env-specific CD8(+) T-cells develop after intragastric vaccination with a Salmonella EnvDNA vaccine vector. Vaccine 2001; 20: 623-629.
76. Zhang L, Gao L, Zhao L, Guo B, Ji K, Tian Y et al. Intratumoral delivery and suppression of prostate tumor growth by attenuated Salmonella enterica serovar typhimurium carrying plasmid-based small interfering RNAs. CancerRes2007; 67: 5859-5864.
77. PagliaP, MedinaE, Arioli I, Guzman CA, ColomboMP. Genetransferindendriticcells, induced byoral DNA vaccination with Salmonella typhimurium, results in protective immunity against a murine fibrosarcoma. Blood 1998; 92: 3172-3176.
78. SizemoreDR, Branstrom AA, SadoffJC. Attenuated ShigellaasaDNAdeliveryvehicle for DNA-mediated immunization. Science 1995; 270:299-302.
79. SizemoreDR, Branstrom AA, SadoffJC. AttenuatedbacteriaasaDNAdeliveryvehicle for DNA-mediated immunization. Vaccine1997; 15: 804-807.
80. Lewis GK. Live-attenuated Salmonella as a prototype vaccine vector for passenger immunogens in humans: are we there yet? Expert Rev Vaccines 2007; 6: 431-440.
81. Gahan ME, Webster DE, Wesselingh SL, Strugnell RA. Impact of plasmid stabilityon oral DNA delivery by Salmonella enterica serovar Typhimurium. Vaccine 2007; 25: 1476-1483.
82. Gahan ME, Webster DE, Wijburg OL, Wesselingh SL, Strugnell RA. Impact of prior immunological exposureon vaccinedeliverybySalmonellaentericaserovar Typhimur- ium. Vaccine 2008; 26: 6212-6220.
83. Pasetti MF, Barry EM, Losonsky G, Singh M, Medina-Moreno SM, Polo JM et al. Attenuated Salmonella enterica serovar Typhi and Shigella flexneri 2a strains muco- sally deliver DNA vaccines encoding measles virus hemagglutinin, inducing specific immune responses and protection in cotton rats. JVirol2003; 77: 5209-5217.
84. Panthel K, Meinel KM, Domenech VE, Retzbach H, Igwe EI, Hardt WD et al. Salmonella pathogenicity island 2-mediated overexpression of chimeric SspH2 proteins for simultaneous induction of antigen-specific CD4 and CD8 T cells. Infect Immun 2005; 73: 334-341.
85. Panthel K, Meinel KM, Sevil VD, Trulzsch K, Russmann H. Salmonella type III- mediated heterologousantigen delivery: aversatileoral vaccination strategytoinduce cellular immunityagainst infectious agents and tumors. Int JMed Microbiol 2008; 298: 99-103.
86. Russmann H. Bacterial type III translocation: a unique mechanism for cytosolic displayofheterologousantigensbyattenuatedSalmonella. IntJMedMicrobiol2003; 293: 107-112.
87. Panthel K, Meinel KM, Sevil VD, Geginat G, Linkemann K, Busch DH et al. Prophylactic anti-tumor immunity against a murine fibrosarcoma triggered by the Salmonella type III secretion system. MicrobesInfect 2006; 8: 2539-2546.
88. Gonzalez C, Hone DM, Noriega F, TacketCO, Davis JR, LosonskyG et al. Salmonella typhi vaccine strain CVD 908 expressing the circumsporozoite protein of Plasmodium falciparum: strain construction and safety and immunogenicity in humans. JInfect Dis1994; 169: 927-931.
89. Wyant TL, Tanner MK, Sztein MB. Potent immunoregulatory effects of Salmonella typhiflagella on antigenic stimulation of human peripheral blood mononuclear cells. Infect Immun 1999; 67: 1338-1346.
90. Wyant TL, Tanner MK, Sztein MB. Salmonella typhi flagella are potent inducers of proinflammatory cytokine secretion by human monocytes. Infect Immun 1999; 67: 3619-3624.
91. + T cell responses in volunteers immunized with Salmonella enterica serovar Typhi strain CVD 908-htrA. JImmunol 2003; 170: 2734-2741.
92. TacketCO, Sztein MB, Wasserman SS, LosonskyG, KotloffKL, WyantTL et al. Phase 2 clinical trial of attenuated Salmonellaentericaserovar typhi oral livevector vaccine CVD 908-htrA in USAvolunteers. Infect Immun 2000; 68: 1196-1201.
93. Tacket CO, Sztein MB, Losonsky GA, Wasserman SS, Nataro JP, Edelman R et al. Safety of live oral Salmonella typhi vaccine strains with deletions in htrA and aroC aroD and immune response in humans. Infect Immun 1997; 65:452-456.
94. Wahid R, Salerno-Goncalves R, Tacket CO, Levine MM, Sztein MB. Cell-mediated immune responses in humans after immunization with one or two doses of oral live attenuated typhoid vaccine CVD 909. Vaccine 2007; 25: 1416-1425.
95. Kilhamn J, Lundin SB, Brevinge H, Svennerholm AM, Jertborn M. T- and B-cell immune responses of patients who had undergone colectomies to oral administration of Salmonella enterica serovar Typhi Ty21a vaccine. Clin Diagn Lab Immunol 2003; 10: 426-430.
96. Lundin BS, Johansson C, Svennerholm AM. Oral immunization with a Salmonella enterica serovar typhi vaccine induces specific circulating mucosa-homing CD4(+) and CD8(+) T cells in humans. Infect Immun 2002; 70: 5622-5627.
97. Salerno-Goncalves R, Pasetti MF, Sztein MB. Characterization of CD8(+) effector T cell responses in volunteers immunized with Salmonella enterica serovar Typhi strain Ty21a typhoid vaccine. JImmunol 2002; 169: 2196-2203.
98. Youngman KR, Lazarus NH, Butcher EC. Lymphocyte homing: chemokines and adhesion molecules in Tcell and IgA plasma cell localization in themucosal immune system. In: Mestecky J, Lamm ME, McGhee JR, Bienenstock J, Mayer L, Strober W (eds). Mucosal Immunology, 3rd edn. Elsevier Academic Press Inc.: Burlington, MA, 2005, pp 667-680.
99. Kantele A, ZivnyJ, Hakkinen M, Elson CO, MesteckyJ. Differential homing commitments of antigen-specific T cells after oral or parenteral immunization in humans. JImmunol 1999; 162: 5173-5177.
100. Svensson M, Marsal J, Ericsson A, Carramolino L, Broden T, MarquezG et al. CCL25 mediates the localization of recently activated CD8alphabeta(+) lymphocytes to the small-intestinal mucosa. JClin Invest2002; 110: 1113-1121.
101. Butcher EC, Williams M, Youngman K, Rott L, Briskin M. Lymphocyte trafficking and regional immunity. AdvImmunol 1999; 72: 209-253.
102. Kantele A, Kantele JM, Savilahti E, Westerholm M, Arvilommi H, Lazarovits A et al. Homing potentials of circulating lymphocytes in humans depend on the site of activation: oral, but not parenteral, typhoid vaccination induces circulating antibody-secreting cells that all bear homing receptors directing them to the gut. J Immunol 1997; 158: 574-579.
103. Salerno-Goncalves R, Wahid R, Sztein MB. Immunization of volunteers with Salmonella enterica serovar Typhi strain Ty21a elicits the oligoclonal expansion of CD8+ T cells with predominant Vp repertoires. Infect Immun 2005; 73: 3521-3530.
104. Wahid R, Salerno-Goncalves R, Tacket CO, Levine MM, Sztein MB. Generation of specific effector and memory T cells with gut and secondary lymphoid tissues homing potential byoral attenuated CVD 909 typhoid vaccine in humans. Mucosal Immunol 2008; 1: 389-398.
105. Woodland DL. Jump-starting the immune system: prime-boosting comes of age. Trends Immunol 2004; 25: 98-104.
106. Reyes-Sandoval A, Harty JT, Todryk SM. Viral vector vaccines make memory T cells against malaria. Immunology2007; 121: 158-165.
107. Dunachie SJ, Hill AV. Prime--boost strategies for malaria vaccine development. JExp Biol 2003; 206: 3771-3779.
108. McConkey SJ, Reece WH, Moorthy VS, Webster D, Dunachie S, Butcher G et al. Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans. Nat Med 2003; 9: 729-735.
109. Epstein JE, CharoenvitY, KesterKE, WangR, NewcomerR, FitzpatrickSet al. Safety, tolerability, and antibodyresponses in humans after sequential immunization with a PfCSP DNA vaccine followed by the recombinant protein vaccine RTS,S/AS02A. Vaccine2004; 22: 1592-1603.
110. Excler JL, Plotkin S. The prime-boost concept applied to HIV preventive vaccines. AIDS 1997; 11(Suppl A): S127-S137.
111. Moorthy VS, Imoukhuede EB, Keating S, Pinder M, Webster D, Skinner MA et al. Phase 1 evaluation of 3 highlyimmunogenic prime-boost regimens, including a 12- month reboosting vaccination, for malaria vaccination in Gambian men. JInfectDis 2004; 189: 2213-2219.
112. Londono-Arcila P, Freeman D, Kleanthous H, O'Dowd AM, Lewis S, Turner AK et al. Attenuated Salmonellaenterica serovar Typhi expressing urease effectivelyimmunizes miceagainstHelicobacterpylorichallengeaspartofaheterologousmucosal priming- parenteral boosting vaccination regimen. Infect Immun 2002; 70: 5096-5106.
113. Vindurampulle CJ, Cuberos LF, Barry EM, Pasetti MF, Levine MM. Recombinant Salmonella enterica serovar Typhi in a prime-boost strategy. Vaccine 2004; 22: 3744-3750.
114. Capozzo AV, Cuberos L, Levine MM, Pasetti MF. Mucosallydelivered Salmonella live vector vaccines elicit potent immune responses against a foreign antigen in neonatal mice born to naive and immune mothers. Infect Immun 2004; 72: 4637-4646.
115. Ramirez K, Capozzo AV, Lloyd SA, Sztein MB, Nataro JP, Pasetti MF. Mucosally delivered Salmonella Typhi expressing the Yersinia pestisF1 antigen elicits mucosal and systemic immunity early in life and primes the neonatal immune system for a vigorous anamnestic response to parenteral F1 boost. JImmunol2009; 182: 1211-1222.
116. Khan S, Chatfield S, Stratford R, Bedwell J, Bentley M, Sulsh S et al. Ability of SPI2 mutant of S typhi to effectively induce antibody responses to the mucosal antigen enterotoxigenic E. coli heat labile toxin B subunit after oral delivery to humans. Vaccine 2007; 25: 4175-4182.
117. Nardelli-Haefliger D, Kraehenbuhl J-P, Curtiss III R, Schodel F, Potts A, Kelly SM et al. Oral and rectal immunization of adult female volunteers with a recombinant attenuated Salmonella typhi vaccine strain. Infect Immun 1996; 64: 5219-5224.
118. TacketCO, KelleySM, Schodel F, LosonskyG, Nataro JP, Edelman R et al. Safetyand immunogenicity in humans of an attenuated Salmonella typhi vaccine vector strain expressing plasmid-encoded hepatitis B antigens stabilized by the Asd-balanced lethal vector system. Infect Immun 1997; 65: 3381-3385.
119. DiPetrillo MD, Tibbetts T, Kleanthous H, Killeen KP, Hohmann EL. Safety and immunogenicity of phoP/phoQ-deleted Salmonella typhi expressing Helicobacter pylori urease in adult volunteers. Vaccine 1999; 18: 449-459.
120. Tacket CO, Galen J, Sztein MB, Losonsky G, Wyant TL, Nataro J et al. Safety and immune responses to attenuated Salmonella enterica serovar Typhi oral live vector vaccines expressing tetanus toxin fragment C. Clin Immunol 2000; 97: 146-153.
121. Bumann D, Metzger WG, Mansouri E, PalmeO, Wendland M, Hurwitz R et al. Safety and immunogenicity of live recombinant Salmonella enterica serovar Typhi Ty21a expressing urease A and B from Helicobacter pylori in human volunteers. Vaccine 2002; 20: 845-852.
122. Metzger WG, Mansouri E, Kronawitter M, Diescher S, Soerensen M, Hurwitz R et al. Impact of vector-priming on the immunogenicity of a live recombinant Salmonella enterica serovar typhi Ty21a vaccine expressing urease A and B from Helicobacter pylori in human volunteers. Vaccine 2004; 22: 2273-2277